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Abstract. Osteoprotegrin (OPG), receptor activator of nuclear 
factor κB (RANK) and RANK ligand (RANKL) are signal 
transducers which have pleiotropic actions. Each tumour 
necrosis factor receptor superfamily member has unique 
structural attributes which directly couples them to signal-
ling pathways involved in cell proliferation, differentiation 
and survival. Previous studies have clinically linked OPG, 
RANK and RANKL to increasing tumour burden, metastatic 
bone involvement and estrogen status. This study aimed to 
establish the potential implications of targeting endogenously 
produced OPG and RANK in the osteotropic breast cancer 
cell line MDA-MB-231 in vitro. Subsequently this study also 
aimed to explore the potential links between these molecules 
with regards to hepatocyte growth factor (HGF) signal-
ling and extracted bone proteins (BME). OPG and RANK 
expression was successfully suppressed using hammerhead 
ribozyme technology. Subsequently effects were explored in 
MDA-MB-231 cell proliferation, matrix adhesion, migration 
and invasion in vitro function assays. Reduced OPG expres-
sion resulted in increased breast cancer cell migration and 
invasion. These increases, particularly invasion, appeared 
to however be reduced under the influence of the exogenous 
stimuli (HGF and BME). In contrast, suppression of RANK 
in MDA-MB-231 breast cancer cells resulted in decreased 
cancer cell proliferation, matrix-adhesion, motility and inva-
sion with little cumulative effect being noted after the addition 
of exogenous stimuli. The complexity of the bone environment 
underpins the vast number of soluble factors and signalling 
pathways which can influence osteotropic cancer behaviour 
and progression. Further work into elucidating all the path-
ways affected could potentially lead to better identification of 
those patients most at risk.
Introduction
Despite advances in breast cancer care and regimens it still 
imposes a large burden on health care systems around the 
world, especially when metastatic disease is detected. Breast 
cancer is associated with latent disease and high relapse rate 
which can often present clinically as bone metastases (1). The 
majority of breast cancer related bone metastases present 
as the osteolytic phenotype, which is identified by loss of 
bone density accompanied by an increase in osteoclast 
numbers (2).
The variability in metastatic cancer patterns is undoubt-
edly influenced by the molecular and cellular characteristics of 
both the tumour cells and the tissue in which they invade (3). It 
was Stephen Paget, through autopsy data, who first established 
a link between breast cancer metastases and the bone, giving 
rise to his ‘seed and soil’ hypothesis (4). As this theory has 
evolved the metastatic cascade has been shown to be a highly 
inefficient multistep process which involves a wide variety 
of factors including integrins, matrix metalloproteinases and 
tumour secreted factors (5,6). Invasion into the bone results in 
the release of a variety of factors, in addition to those produced 
by the tumour cells, which generate a feedback loop to the 
tumour cells enhancing tumour cell dormancy, survival and 
growth in the bone marrow and the microenvironment (7). 
However, much still remains unknown of how these factors 
interact with each other and the disseminating tumour cells 
to culminate in bone metastases and how best these can be 
targeted in therapies.
Members of the tumour necrosis factor receptor super-
family (TNFRSF) osteoprotegrin (OPG), receptor activator of 
nuclear κB (RANK) and RANK ligand (RANKL) have been 
shown to be integral molecular regulators in the bone remod-
elling cycle. The RANKL:OPG ratio is a major determinant of 
bone mass, both physiologically and patho-physiologically (8). 
Osteoblasts have been shown to incorporate both pro- and anti- 
bone resorptive signals and thus control the bone remodelling 
response by altering the expression of RANKL and secretion 
of its inhibitor OPG (9,10). RANK, expressed on the surface 
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of osteoclasts, through binding to RANKL, expressed on the 
surface of osteoblasts, promotes osteoclast differentiation and 
maturation, thus promoting bone resorption. OPG, a soluble 
decoy receptor for RANKL, secreted by osteoblasts, inhibits 
RANK interaction thus promoting osteoblast survival and 
hence bone formation. However, OPG, RANK and RANKL 
have also been linked to tumourigenesis in a variety of 
cancers which have a predisposition to form bone metastases. 
Both circulating RANKL and OPG have previously been 
identified as novel biomarker candidates for predicting bone 
metastases in breast cancer patients (11,12). Quantitative PCR 
and immunohistochemistry have shown negative correlations 
between estrogen receptor status and levels of OPG, RANK 
and RANKL (13).
There has also been some in vitro evidence to suggest that 
endogenously produced OPG, from breast cancer cells or bone 
marrow stromal cells, can also promote breast cancer cell 
survival through inhibition of TNF related apoptosis inducing 
ligand (TRAIL) (14,15). This inhibition occurs as OPG acts as a 
decoy receptor for the TRAIL receptor, though with less affinity 
than that seen with RANKL, therefore blocking the apoptotic 
pathway. This prevention of apoptosis through TRAIL inhibi-
tion has also been shown, in the MDA-MB-231 breast cancer 
cell line, to result in the up regulation of RANKL thus contri-
buting to the ‘vicious’ bone cycle between tumour cells and 
bone cells by further enhancing osteolysis and the release of 
growth factors which can further enhance tumour growth (16).
The bone microenvironment is a complex combination 
of cells, growth factors and cytokines. Trying to isolate the 
factors which are crucial components in facilitating the estab-
lishment of bone metastases is a substantial challenge. One 
of the factors, which have been shown to influence tumouri-
genesis traits and cancer progression is hepatocyte growth 
factor (HGF), also known as scatter factor (17-19). Despite its 
discovery 30 years ago its wide and complex influences on 
cancer cells, the metastatic cascade and tumour microenviron-
ments remain under intense investigation for potential new 
targeted therapies (20,21).
In the present study the targeting of OPG and RANK in 
bone metastasis derived breast cancer cells (MDA-MB-231 
cells) was explored. These manipulated cells were then exposed 
to the influences of HGF and a bone protein-like environment 
to explore the potential implications on HGF signalling thus 
potentially altering disease progression.
Materials and methods
Ethics statement. All research involving human tissue 
was carried out under the Panel B Bro Taf Research Ethics 
Committee for the Bro Taf Health Board, Cardiff, UK. All data 
were analysed anonymously and informed written consent was 
given (Bro Taf Health Board, 2007).
Cell lines and treatments. Human breast cancer MDA-MB-231 
cells were purchased from the American Type Culture 
Collection (ATCC, Rockville, MD, USA). MDA-MB-231 
cells were maintained in Dubecco's modified Eagle's medium 
(DMEM) (PAA Laboratories Ltd., Somerset, UK) supple-
mented with penicillin, streptomycin and 10% foetal calf serum 
(PAA Laboratories Ltd.) and incubated at 37˚C, 5% CO2 and 
95% humidity. Hepatocyte growth factor was a kind gift from 
Dr T. Nakamura (Osaka University Medical School, Osaka, 
Japan). Bone proteins were extracted from fresh human bone 
tissues collected immediately after hip replacement under the 
local health board ethics committee guidelines. Bones were 
crushed at ice cold temperatures and subsequently processed 
in a Bioraptor sonicator (wolf Laboratories, York, UK) to 
extract matrix proteins (22). Throughout this study HGF was 
used at a final concentration of 40 ng/ml, whilst the BME 
extract from the femoral heads was used at a final concentra-
tion of 50 µg/ml.
Generation of MDA-MB-231 breast cancer cells with 
suppressed OPG or RANK expression. OPG and RANK 
expression were targeted in human MDA-MB-231 breast 
cancer cells using ribozyme transgenes specifically gener-
ated to target and cleave each transcript. This methodology 
has been previously reported (23,24). Briefly, ribozyme 
transgene sequences were designed based on Zukers predicted 
secondary mRNA structure using Zukers RNA Mfold 
program (25) and were synthesised by Sigma-Aldrich (Poole, 
Dorset, UK) (Table I). Ribozymes were subsequently cloned 
into a pEF6/V5-His-TOPO plasmid vector (Invitrogen, 
Paisley, UK). Both control pEF6 plasmids, containing no 
insert, and plasmids containing the relevant ribozyme trans-
gene were transfected separately into MDA-MB-231 breast 
cancer cells using electroporation. Following transfection, 
these cells underwent a selection period and subsequent 
verification of OPG or RANK knockdown. Cells containing 
the ribozyme transgenes were termed MDA-MB-231OPGKD 
or MDA-MB-231RANKKD and were compared throughout the 
study to control MDA-MB-231 cells containing the closed 
control plasmid, termed MDA-MB-231pEF6.
RNA extraction and reverse transcription-polymerase chain 
reaction (RT-PCR). Cells were grown to confluence in a 25-cm2 
flask before RNA was extracted using total RNA isolation 
(TRI) reagent (Sigma) in accordance with the supplied protocol. 
RNA was subsequently quantified using a spectrophotometer 
(Implen Nanophotometer, Muchen, Germany) configured to 
detect single strand RNA (µg/µl). RNA was standardised to 
500 ng and used as a template to generate cDNA using high 
capacity cDNA reverse transcription kit (Applied Biosystems, 
Manchester, UK). Following cDNA synthesis, sample quality 
and uniformity was normalised against GAPDH expression 
(primer details in Table II). The amplifluor system (Intergen 
Inc., New York, NY, USA) was utilised with qPCR Master 
Mix (ABgene, Surrey, UK). Conditions for qPCR were; 15 min 
initial 95˚C period followed by 60 cycles of 95˚C for 15 sec, 
55˚C for 60 sec and 72˚C for 20˚C sec.
SDS-PAGE and western blotting. Protein was extracted from 
a confluent 75-cm2 tissue culture flask of MDA-MB-231 cells. 
Cells were detached and lysed in a buffer comprising 50 mM 
Tris-base, 5 mM EGTA, 150 mM NaCl, 1% Triton X-100, 
100 µg/ml PMSF, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 
5 mM sodium vanadate and 50 mM sodium fluoride on a rotor 
wheel for 1 h before removal of insolubles through centrifuga-
tion at 13,000 g. The Bio-Rad DC protein assay kit (Bio-Rad 
Laboratories, CA, USA) was used to quantify protein levels in 
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each sample and samples were subsequently standardised to 
2 mg/ml and diluted in 2X concentrate Laemmli sample buffer 
(Sigma) before being boiled for 5 min. Samples were loaded 
onto a 10% acrylamide gel and separated electrophoretically. 
Following separation the proteins were blotted onto a PVDF 
membrane (Merck-Millipore, Feltham, UK). Proteins were 
detected using the Merck-Millipore SNAP i.d. protein detec-
tion system. OPG expression was detected using anti-OPG 
antibody [R&D Systems, Abingdon, UK (BAF805)], RANK 
expression was detected using anti-RANK antibody [Santa 
Cruz Biotechnology, Inc., CA, USA (sc-9072)]. To assess 
uniformity of the samples GAPDH expression was also detected 
using anti-GAPDH antibody [Santa Cruz Biotechnology, 
Inc. (sc-32233)]. Following binding of the primary antibody, 
the membranes were probed with peroxidase conjugated 
anti-goat (OPG), anti-rabbit (RANK) or anti-mouse (GADPH) 
secondary antibodies (Sigma). Expression was visualised 
using the Luminata chemiluminescence detection kit (Merck-
Millipore) and detected using a UVIProChem camera system 
(UVItec Ltd., Cambridge, UK).
Table I. Primers designed for ribozyme synthesis.
Target Ribozyme Primer name Primer sequence (5'-3')
  T7F TAATACGACTCACTATAGGG
  RBBMR TTCGTCCTCACGGACTCATCAG
  RBTPF CTGATGAGTCCGTGAGGACGAA
OPG OPG ribozyme 1 OPGRIB1F CTGCAGCTCCTTGCACACGGGGCTGCAGTATACT
   GATGAGTCCGTGAGGA
  OPGRIB1R ACTAGTACACAGACAGCTGGCACACCAGTGACGA
   GTGTTTCGTCCTCACGGACT
 OPG ribozyme 2 OPGRIB2F CTGCAGACACTGCAATTTGTGTGTTTTCTACTGGG
   TGCTTTACTGATGAGTCCGTGAGGA
  OPGRIB2R ACTAGTTCTTCTCAAATGAGACGTCATTTCGTCCT
   CACGGACT
 OPG ribozyme 3 OPGRIB3F CTGCAGGGTAACATCTATTCCACATTTTGAGTTCTG
   ATGAGTCCGTGAGGA
  OPGRIB3R ACTAGTTCCGGAAACAGTGAATTTCGTCCTCACGG
   ACT
RANK RANK ribozyme 1 RANKRIB1F CTGCAGCGCGCGGGGCCATGGCGCGGCTGATGA
   GTCCGTGAGGA
  RANKRIB1R ACTAGTGCCGCGGCGCCGCCAGCCTGTTTCGTCC
   TCACGGACT
 RANK ribozyme 2 RANKRIB2F CTGCAGCTCATAATGCTTCTCACTGGCTGATGAGT
   CCGTGAGGA
  RANKRIB2R ACAGTCTTTGCAGATCGCTCCTCCATGTTTCGTCC
   TCACGGACT
 RANK ribozyme 3 RANKRIB3F CTGCAGGTACTTTCCTGGTTCACATTTGTCTGATG
   AGTCCGTGAGGA
  RANKRIB3R ACTAGTAGCATTATGAGCATCTGGGACGGTGCTGT
   TTCGTCCTCACGGACT
 RANK ribozyme 4 RANKRIB4F CTGCAGTGCTGACCAAAGTTTGCCGTGTGTGCTG
   ATGAGTCCGTGAGGA
  RANKRIB4R ACTAGTGGAGTCCTCAGGTGACAGTTGTGTCAGTT
   TCGTCCTCACGGAC
 RANK ribozyme 5 RANKRIB5F CTGCAGCTGGCATCTTCGCCTTGTGCGTAGGCTG
   ATGAGTCCGTGAGGA
  RANKRIB5R ACTAGTGTCAGGGCACATGTGTAGGAGGTGGTTTC
   GTCCTCACGGACT
OwEN et al:  OPG AND BONE METASTASES922
In vitro cell proliferation assay. An in vitro cell proliferation 
assay was used to examine the impact of OPG or RANK 
suppression on cell proliferation. Cells were seeded into 
two 96-well plates at a seeding density of 3x103 cells/well 
with or without treatment and incubated for 1 and 5 days. 
Following incubation, cells were fixed in 4% formaldehyde 
(v/v) and stained with 0.5% crystal violet (w/v). Subsequently, 
10% acetic acid (v/v) was used to extract the crystal violet 
stain and cell density determined through spectrophotometric 
analysis using a Bio-Tek Elx800 multi-plate reader (Bio-Tek 
Instruments Inc., VT, USA).
In vitro Matrigel matrix adhesion assay. Cell-matrix adhe-
sion was assessed using a modified in vitro Matrigel adhesion 
assay (26). In brief, wells in a 96-well plate were pre-coated 
with 5 µg of Matrigel (BD Matrigel matrix, Matrigel base-
ment membrane matrix, Biosciences). Cells were seeded at 
4.5x104 cells/well with or without treatment and left to adhere 
to the Matrigel for 40 min at 37˚C with 5% CO2. Adherent 
cells were fixed in 4% formaldehyde (v/v) and stained with 
0.5% crystal violet (w/v). Subsequently, adherent cells were 
visualised under the microscope and representative images 
captured for analysis.
In vitro cell motility assay. Cell motility was assessed using a 
cytodex-2 bead motility assay as previously described (27,28). 
In brief, 1x106 cells were incubated in 10 ml of complete 
medium supplemented with 20 mg of cytodex-2 beads. The 
following day, beads were washed twice with complete medium 
before being resuspended, added to the 96-well plate with or 
without treatment and incubated for 4 h at 37˚C with 5% CO2. 
Migrated cells were fixed in 4% formaldehyde (v/v) and 
stained with 0.5% crystal violet (w/v). Subsequently, adherent 
cells were visualised under the microscope and representative 
images captured for analysis.
In vitro Matrigel cell invasion assay. Cell invasiveness was 
assessed using an in vitro Matrigel invasion assay modified 
from refs. 29,30. In brief, transwell inserts containing 8-µm 
pores (Falcon, 24-well format, Greiner Bio-One, Germany) 
were placed in a 24-well plate (Nunc, Greiner Bio-One) and 
coated with 50 µg of Matrigel (BD Matrigel matrix, Matrigel 
Table II. Primers for conventional RT-PCR and real-time qPCR.
Gene Primer name Primer sequence (5'-3') Optimal annealing  Product
   temperature (˚C) size (bp)
OPG OPGF8 GAACCCCAGAGCGAAATACA 55 509
 OPGR8 CGGTAAGCTTTCCATCAAGC
 OPGF1 GTTCTGCTTGAAACATAGGAG 55 115
 OPGZR1 ACTGAACCTGACCGTACACGTCT
  CATTTGAGAAGAACC
RANK RANKF9 CAGAGCACAGTGGGTTCAGA 55 462
 RANKR9 GATGATGTCGCCCTTGAAGT
 RANKF2 TCTGATGCCTTTTCCTCCAC 55 119
 RANKZR2 ACTGAACCTGACCGTACATGGCA
  GAGAAGAACTGCAAA
RANKL RANKLF9 GACTCCATGAAAATGCAGAT 55 500
 RANKLR9 TCCTTTCATCAGGGTATGAG
 RANKLF1 AAGGAGCTGTGCAAAAGGAA 55 74
 RANKLZR1 ACTGAACCTGACCGTACAATCCA
  CCATCGCTTTCTCTG
GAPDH GAPDHF10 AGCTTGTCATCAATGGAAAT 55 593
 GAPDHR10 CTTCACCACCTTCTTGATGT
 GAPDHF CTGAGTACGTCGTGGAGTC 55   93
 GAPDHZR ACTGAACCTGACCGTACACAGAG
  ATGATGATGACCCTTTTG
PDPL PDPLF GAATCATCGTTGTGGTTATG 55
 PDPLZR ACTGAACCTGACCGTACACTTTCA
  TTTGCCTATCACAT
ACTGAACCTGACCGTACA represents the Z sequence.
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basement membrane matrix, Biosciences). Subsequently 
2x104 cells/insert were added to the insert and 1 ml of medium 
was added to the bottom of the 24-well plate to sustain any 
invaded cells. The plate was incubated for 3 days at 37˚C 
with 5% CO2 after which inserts were cleaned to remove any 
non-invaded cells, before invaded cells were fixed in 4% form-
aldehyde (v/v) and stained with 0.5% crystal violet (w/v). 
Subsequently, invaded cells were visualised under the micro-
scope and representative images captured for analysis.
Statistical analysis. The Sigma plot 11.0 statistical software 
package was used to assess statistical differences between the 
OPG or RANK suppressed MDA-MB-231 cells compared 
to the pEF6 vector control MDA-MB-231 cells using the 
Student's two tailed t-test or non-parametric Mann-whitney 
U test. Experimental procedures were repeated a minimum 
of 3 independent times. Data represent mean values ± SEM, 
p-values of ≤0.05 were regarded as statistically significant.
Results
Expression of OPG and RANK has previously been establi-
shed in three breast cancer cell lines (31). There are also 
potential links between the expression profiles of OPG, 
RANK, the pro-tumourigenic stimuli HGF and the bone 
microenvironment.
Suppression of molecules of interest using ribozyme trans-
genes. OPG or RANK expression was successfully targeted 
in MDA-MB-231 breast cancer cells following transfec-
tion with anti-OPG or anti-RANK ribozyme transgenes 
contained within a pEF6 plasmid. Reduced OPG transcript 
expression was seen in MDA-MB-231OPGKD cells compared 
to the MDA-MB-231pEF6 cells using both RT-PCR and qPCR 
(Fig. 1A and B). The result was subsequently confirmed at a 
protein level using western blotting (Fig. 1C).
Reduced RANK transcript expression was seen in 
MDA-MB-231RANKKD cells compared to the MDA-MB-231pEF6 
cells using both RT-PCR and qPCR (Fig. 1D and E). This was 
subsequently confirmed at a protein level using western blot-
ting (Fig. 1F).
Impact on MDA-MB-231 breast cancer cell proliferation. 
MDA-MB-231 breast cancer cell proliferation over 5 days was 
not significantly altered after suppression of OPG compared 
to the control cells (Fig. 2A). Suppression of RANK in 
MDA-MB-231 breast cancer cells resulted in a statistically 
significant decrease in cell proliferation after 5-day incubation 
compared to the control cells (Fig. 2B, p=0.029). Individual 
40 ng/ml HGF and 50 µg/ml BME treatments significantly 
increased MDA-MB-231pEF6 cell proliferation after 5-day incu-
bation compared to the untreated control (Fig. 2C, p=0.029). 
A similar pattern was seen after incubation with a combined 
40 ng/ml HGF and 50 µg/ml BME treatment; however, this 
did not reach statistical significance. MDA-MB-231OPGKD 
(Fig. 2D) and MDA-MB-231RANKKD (Fig. 2E) cell proliferation 
was less responsive to HGF and BME treatments compared to 
those observed in the MDA-MB-231pEF6 cells. No statistically 
significant changes were observed in either of the suppressed 
cell lines compared to their respective untreated controls.
Impact on MDA-MB-231 breast cancer cell-matrix adhesion. 
Suppression of OPG in MDA-MB-231 breast cancer cells did 
not appear to affect cell-matrix adhesion (Fig. 3A). In contrast, 
Figure 1. Verification of ribozyme transgene knockdown of OPG and RANK in MDA-MB-231 cells. Reduced expression of OPG and RANK were confirmed 
at a transcript level using RT-PCR (A and D) and qPCR (B and E) compared to the control cell line. Western blotting was used to confirm knockdown of OPG 
and RANK at a protein level (C and F respectively). PCR and western blotting were normalised against GAPDH. Representative images and data shown. 
**p≤0.01, ***p≤0.001.
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suppression of RANK in MDA-MB-231 breast cancer cells 
resulted in a statically significant decrease in cell-matrix adhe-
sion in vitro (Fig. 3B, p=0.029). MDA-MB-231pEF6 cell-matrix 
adhesion appeared unaffected under the influence of treat-
ment with 40 ng/ml HGF and/or 50 µg/ml BME (Fig. 3C). A 
similar trend was seen in the MDA-MB-231OPGKD cells treated 
individually with 40 ng/ml HGF or 50 µg/ml BME (Fig. 3D), 
however, when these treatments were combined cell-matrix 
adhesion was significantly reduced compared to the untreated 
cells (p=0.024). In the MDA-MB-231RANKKD cells treatment 
with 40 ng/ml HGF and/or 50 µg/ml BME did not appear to 
significantly affect cell-matrix adhesion (Fig. 3E).
Impact on MDA-MB-231 breast cancer cell motility. 
Suppression of OPG expression in MDA-MB-231 cells resulted 
in significantly increased cell motility in vitro compared to 
the control cells (Fig. 4A, p=0.029). In contrast, suppression 
of RANK in MDA-MB-231 breast cancer cells resulted in 
significantly decreased cell motility in vitro (Fig. 4B, p≤0.001). 
when MDA-MB-231pEF6 cells were treated with 40 ng/ml 
HGF cell motility was increased, however, this did not pass 
the statistical threshold (Fig. 4C). However, no noticeable 
effect was seen on MDA-MB-231pEF6 cell motility when cells 
were treated with 50 µg/ml BME. when both treatments were 
combined MDA-MB-231pEF6 cell motility was significantly 
increased compared to the untreated control cells (Fig. 4C, 
p=0.029). In contrast, treatment of MDA-MB-231OPGKD cells 
with 40 ng/ml HGF or 50 µg/ml BME did not appear to impact 
MDA-MB-231 cell motility compared to the untreated control 
(Fig. 4D). when these treatments were combined increased cell 
motility was observed compared to the untreated control cells, 
however, this trend also failed to reach the statistically signifi-
cant threshold. Similar responses to the exogenous HGF and 
BME treatments were also seen in the MDA-MB-231RANK KD 
cells, in which cell motility was only marginally affected by 
these factors (Fig. 4E).
Impact on MDA-MB-231 breast cancer cell invasion. 
Suppression of OPG resulted in significantly increased cell 
invasiveness compared to the control cells (Fig. 5A, p=0.037). 
Figure 2. Impact of OPG and RANK knockdown on MDA-MB-231 cell proliferation in vitro. Suppression of OPG expression had no effect on MDA-MB-231 
cell proliferation after 5-day incubation compared to MDA-MB-231pEF6 control cells (A). Reduced RANK expression in MDA-MB-231 cells resulted in a 
significant decrease in cell proliferation after 5-day incubation compared with control cells (B). Treatment of the MDA-MB-231pEF6 control cell line with 
40 ng/ml HGF, 50 µg/ml BME or a combination of 40 ng/ml HGF and 50 µg/ml BME resulted in a significant increase in cell proliferation after 5-day incuba-
tion compared to the untreated cells (C). After 5-day treatment of MDA-MB-231OPGKD cells or MDA-MB-231RANKKD cells with 40 ng/ml HGF, 50 µg/ml BME 
or a combination of 40 ng/ml HGF and 50 µg/ml BME no changes were seen compared to the respective untreated cells (D and E). Data represent the mean of 
4 independent repeats, error bars represent SEM. *p≤0.05.
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However, suppression of RANK in MDA-MB-231 cells resulted 
in a significant decrease in breast cancer cell invasion in vitro 
compared to the control cells (Fig. 5B, p=0.002). Treatment of 
MDA-MB-231pEF6 cells with 40 ng/ml HGF or 50 µg/ml BME 
increased cell invasion in vitro compared to untreated cells, 
however, these trends did not reach the statistically significant 
threshold (Fig. 5C). when these treatments were added in 
combination no noticeable effect on MDA-MB-231 cell inva-
sion was observed. In contrast, when MDA-MB-231OPGKD cells 
were treated with 40 ng/ml HGF or a combination of 40 ng/ml 
HGF and 50 µg/ml BME significant reductions in cell inva-
sion were observed compared to the untreated cells (Fig. 5D, 
p=0.002 and 0.013, respectively). The largest reduction in 
cell invasion was observed under the individual 50 µg/ml 
BME treatment; however, this trend did not reach statistical 
significance. MDA-MB-231RANKKD cell invasion under both 
individual exogenous treatments increased in vitro compared 
to the untreated control cells in a similar trend to that observed 
in the MDA-MB-231pEF6 control cells, though none of these 
changes reached a significant level (Fig. 5E). However, inter-
estingly a combined treatment appeared to have little impact 
on breast cancer cell invasion.
Discussion
with the combined efforts of surgeons, oncologists and 
research, treatment options for primary breast cancer have 
improved. However, one aspect of the disease which still 
remains poorly understood and controlled is its metastatic 
spread, particularly to the bone. Through the recent licensing 
of Denosumab, the neutralising RANKL antibody, some 
progress has been achieved; however, there still remains no 
preventative measures or screening tools which can identify 
those most at risk.
Figure 3. Impact of reduced OPG and RANK expression in MDA-MB-231 cells on cell-matrix adhesion in vitro. Reduced OPG expression did not alter 
MDA-MB-231 cell-matrix adhesion compared with control cells (A). Reduced RANK expression resulted in a significant decrease in MDA-MB-231 cell-matrix 
adhesion compared with control cells (B). when MDA-MB-231pEF6 control cells were treated with 40 ng/ml HGF or 50 µg/ml BME or a combination of 
40 ng/ml HGF and 50 µg/ml BME did not significantly alter MDA-MB-231 cell-matrix adhesion (C). MDA-MB-231OPGKD cells treated with 40 ng/ml HGF 
or 50 µg/ml BME also did not alter cell-matrix adhesion, however, a combined of HGF and BME treatment significantly decreased cell matrix adhesion (D). 
MDA-MB-231RANKKD cells treated with 40 ng/ml HGF, 50 µg/ml BME or combined HGF and BME did not affect cell-matrix adhesion compared to the 
untreated cells (E). Data represent the mean of 4 independent repeats, error bars represent SEM. *p≤0.05.
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whilst many previous studies have considered the role 
OPG plays in the inhibition of TRAIL and thus apoptosis 
(15), few reports consider the molecular implications in breast 
cancer progression to the bone. Of interest from this study was 
the lack of proliferation response to the exogenous HGF and 
BME treatments in the OPG suppressed cells which had been 
seen in the control cells. Of similar interest was that this lack 
of response to the exogenous stimuli (HGF and BME) was also 
seen in the cell-matrix adhesion assays. This study has also 
highlighted the potential roles suppression of OPG may have 
in increasing breast cancer cell motility and invasion in addi-
tion to its role in preventing apoptosis. Suppression of OPG 
resulted in significantly more motile MDA-MB-231 breast 
cancer cells compared to the untreated control. However, also 
of interest was that the exogenous treatments did not appear to 
have any further effect on this cell function. Though suppres-
sion of OPG resulted in significantly increased cell invasion, of 
note was that all the exogenously added treatments resulted in 
decreased cell invasion. This is of particular interest because, 
though not reaching statistical significance in the control cell 
line, treatment with HGF or BME resulted in increases in cell 
invasion. This highlights that OPG may play an integral role 
in breast cancer cells homing to the bone environment. This 
present data therefore suggest that expression of OPG may 
result in the suppression of these aggressive cancer cell traits 
and may also contribute to the regulation of the MDA-MB-231 
breast cancer cell response to various environmental stimuli, 
including HGF, once bone metastases have already been 
established. This study implies in vitro the targeting of OPG 
also results in a response suppression to the oncogenic factor 
HGF. This is an interesting observation given a number of 
reports which demonstrate the potential prognosis effect of 
its receptor, c-MET expression and its phosphorylated version 
could have on breast cancer survival (32). However, an in vivo 
study by Zinonos et al (33) suggested that pharmacological 
inhibition of OPG though beneficial for bone health (reduc-
tion in osteolysis) also resulted in an increase in formation 
of soft tissue metastases. This was supported by weichhaus 
et al (34) demonstrating that suppression of OPG in a chick 
embryo model reduced metastasis. These data and that from 
Figure 4. Effect of OPG and RANK knockdown on MDA-MB-231 cell motility. MDA-MB-231OPGKD cells showed significantly increased motility com-
pared with MDA-MB-231pEF6 control cells (A). Reduced RANK expression resulted in a significant decrease in MDA-MB-231 cell motility compared to 
MDA-MB-231pEF6 control cells (B). Treatment of MDA-MB-231pEF6 control cells with 40 ng/ml HGF or 50 µg/ml BME did not significantly alter cell motility. 
However, a combination of 40 ng/ml HGF and 50 µg/ml BME significantly increased cell motility compared to the untreated control (C). Treatment of 
MDA-MB-231OPGKD or MDA-MB-231RANKKD cells with 40 ng/ml HGF and/or 50 µg/ml BME did not significantly impact cell motility (D and E, respectively). 
Data represent the mean of 4 independent repeats, error bars represent SEM. *p≤0.05, **p≤0.01, ***p≤0.001.
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elsewhere in the scientific literature therefore suggest that the 
targeting of OPG in breast cancer may be a double edged 
sword (35,36).
In contrast, the suppression of RANK in MDA-MB-231 
breast cancer cells resulted in decreased responses in all the 
traits studied. Cell proliferation was significantly decreased 
after 5-day incubation compared to the control. Similar lack of 
response to the exogenous treatments was seen in the RANK 
suppressed cells. Interestingly, individual HGF or BME treat-
ments increased cell-matrix adhesion and cell invasion in 
the RANK suppressed cells, though these did not pass the 
threshold for statistical significance. Most previous studies have 
overexpressed RANK in breast cancer models and reported 
increases in aggressive cell behaviour, including increased 
cell migration and invasion as well as greater metastatic bone 
colonisation (37). Casimiro et al (38) in their study found a 
link between bone-seeking RANK positive subclones of 
MDA-MB-231 cells and increased cell migration and invasion 
through the RANKL JNK and ERK 1/2 signalling pathway. 
This demonstrates that the three molecules, OPG, RANK 
and RANKL, originally linked to regulation of bone turnover 
have other roles, potentially even pro-metastatic ones in breast 
cancer. The data reported here suggest that the targeting of 
RANK affects breast cancer cell behaviour associated with a 
metastatic phenotype (i.e., migration and invasion) in its own 
right, changes which subsequently remained unaltered when 
exposed to a bone-like environment. This therefore opens the 
possibility to explore the combination of dual therapies which 
combine targeting of breast cancer cell expressed RANKL 
(Denosumab) and RANK.
The human body is an intricate combination of a variety 
of cells and factors which could never be replicated in a 
2-D model, possibly accounting for the disparity between 
the in vitro results and our previously published clinical data. 
Isolating OPG and RANK in this model system has demon-
strated, particularly with OPG that they may play roles in bone 
metastases associated with breast cancer. Further scientific 
study is now necessary to fully understand the downstream 
Figure 5. Impact of reduced OPG and RANK expression on MDA-MB-231 cell invasion in vitro. MDA-MB-231OPGKD cells showed significantly increased cell 
invasion compared with MDA-MB-231pEF6 control cells (A). MDA-MB-231RANKKD cells showed reduced cell invasion compared with MDA-MB-231pEF6 control 
cells (B). Treatment of MDA-MB-231pEF6 control cells with 40 ng/ml HGF, 50 µg/ml BME or a combination of 40 ng/ml HGF and 50 µg/ml BME do not impact 
cell invasion (C). Treatment of MDA-MB-231OPGKD cells with 40 ng/ml HGF or a combination of 40 ng/ml HGF and 50 µg/ml BME resulted in a significant 
decrease in cell invasion (D). MDA-MB-231RANKKD cells treated with 40 ng/ml HGF, 50 µg/ml BME or combined 40 ng/ml HGF and 50 µg/ml BME showed 
non-significant increases in cell invasion (E). Data represent the mean of 3 independent repeats, error bars represent SEM. *p=≤0.05, **p≤0.01.
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molecules of OPG which inf luence this tumourigenic 
behaviour beyond the inhibition of TRAIL-induced apoptosis.
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